Allianz Asset Management GmbH Decreases Stake in Twist Bioscience Co. (NASDAQ:TWST)

Allianz Asset Management GmbH lessened its stake in Twist Bioscience Co. (NASDAQ:TWSTGet Rating) by 0.7% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 1,608,637 shares of the company’s stock after selling 11,301 shares during the quarter. Allianz Asset Management GmbH owned 2.86% of Twist Bioscience worth $79,434,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in TWST. Advisor Group Holdings Inc. lifted its stake in Twist Bioscience by 7.8% during the fourth quarter. Advisor Group Holdings Inc. now owns 4,212 shares of the company’s stock worth $346,000 after purchasing an additional 305 shares during the last quarter. Teacher Retirement System of Texas lifted its stake in Twist Bioscience by 4.8% during the first quarter. Teacher Retirement System of Texas now owns 9,234 shares of the company’s stock worth $456,000 after purchasing an additional 421 shares during the last quarter. HighTower Advisors LLC lifted its stake in Twist Bioscience by 13.4% during the fourth quarter. HighTower Advisors LLC now owns 3,686 shares of the company’s stock worth $287,000 after purchasing an additional 435 shares during the last quarter. Pictet & Cie Europe SA lifted its stake in Twist Bioscience by 10.4% during the first quarter. Pictet & Cie Europe SA now owns 5,155 shares of the company’s stock worth $255,000 after purchasing an additional 487 shares during the last quarter. Finally, KRS Capital Management LLC purchased a new stake in Twist Bioscience during the fourth quarter worth approximately $46,000.

Twist Bioscience Trading Up 4.9 %

NASDAQ:TWST opened at $41.99 on Friday. The firm has a market cap of $2.37 billion, a P/E ratio of -10.60 and a beta of 1.21. The stock’s 50 day simple moving average is $43.84 and its 200-day simple moving average is $41.14. Twist Bioscience Co. has a 12-month low of $25.07 and a 12-month high of $139.99.

Twist Bioscience (NASDAQ:TWSTGet Rating) last released its earnings results on Friday, August 5th. The company reported ($1.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.30) by $0.22. Twist Bioscience had a negative return on equity of 29.61% and a negative net margin of 112.91%. The business had revenue of $56.10 million for the quarter, compared to analyst estimates of $52.06 million. During the same quarter in the previous year, the company posted ($0.82) earnings per share. The company’s revenue for the quarter was up 60.3% compared to the same quarter last year. Research analysts forecast that Twist Bioscience Co. will post -4.53 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TWST has been the topic of several research analyst reports. SVB Leerink lifted their price target on Twist Bioscience from $45.00 to $50.00 and gave the stock a “market perform” rating in a research report on Monday, August 8th. Barclays lifted their price target on Twist Bioscience from $45.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday, August 8th. Finally, Robert W. Baird lifted their price target on Twist Bioscience from $43.00 to $56.00 in a research report on Monday, August 8th.

Insider Buying and Selling

In related news, CFO James M. Thorburn sold 9,000 shares of the company’s stock in a transaction on Wednesday, August 17th. The stock was sold at an average price of $48.51, for a total transaction of $436,590.00. Following the transaction, the chief financial officer now owns 38,831 shares of the company’s stock, valued at $1,883,691.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Twist Bioscience news, SVP Paula Green sold 10,067 shares of the business’s stock in a transaction on Wednesday, June 15th. The stock was sold at an average price of $30.47, for a total transaction of $306,741.49. Following the sale, the senior vice president now directly owns 14,727 shares in the company, valued at $448,731.69. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO James M. Thorburn sold 9,000 shares of the business’s stock in a transaction on Wednesday, August 17th. The stock was sold at an average price of $48.51, for a total value of $436,590.00. Following the sale, the chief financial officer now owns 38,831 shares in the company, valued at $1,883,691.81. The disclosure for this sale can be found here. Insiders have sold 21,038 shares of company stock valued at $824,830 over the last quarter. Company insiders own 3.10% of the company’s stock.

Twist Bioscience Profile

(Get Rating)

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

See Also

Institutional Ownership by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.